GleamWall
中文EN

ABPO Abpro Holdings, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1893219 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY119.1%
TTM EPS YoY108.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR-26.1%

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA46.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets156.9%
Debt / equity—
Current ratio0.62x
Interest coverage-22.07x

Cash quality & payout

Operating cash flow / net income-3.00x
Accruals ratio184.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$9,000$13,000$108,000$243,000$313,000$325,000$514,000$642,000
SG&A expense$1.17M$920,000$1.79M$1.09M$1.95M$2.63M$2.26M$1.47M
Operating income-$1.18M-$933,000-$1.90M-$1.34M-$2.26M-$2.96M-$7.99M-$1.93M
Interest expense$2,000$23,000$24,000$193,000$174,000$737,000$81,000$164,000
Pretax income——————-$5.57M-$307,446
Income tax———————$27,654
Net income-$940,000-$1.03M$5.64M-$1.66M-$2.98M-$3.89M-$3.33M-$335,100
EBITDA-$1.17M-$930,000-$1.89M-$1.33M-$2.26M-$2.95M-$7.99M-$1.92M
EPS (basic)-0.16-0.23—-0.63-1.56-2.29—-3.27
EPS (diluted)-0.16-0.23—-0.63-1.56-2.29—-3.27
Weighted avg. shares (diluted)5.90M4.49M—2.61M1.92M1.70M—640,606
Balance sheet
Cash & equivalents$4.24M$5.41M$82,000$343,000$2.03M$1.41M$2.99M$141,000
Receivables—$183,000$183,000$271,000$342,000$331,000$183,000—
Current assets$5.08M$6.70M$896,000$1.23M$3.07M$2.22M$3.78M$1.56M
PP&E, net————$27,000$31,000$37,000—
Total assets$5.24M$6.87M$1.06M$1.70M$3.48M$2.80M$4.66M$7.86M
Current liabilities$8.22M$9.12M$9.35M$17.30M$20.43M$20.61M$19.61M$9.04M
Total liabilities$8.22M$9.12M$9.35M$17.30M$20.43M$20.61M$19.61M$18.58M
Shareholders' equity-$3.53M-$2.80M-$8.83M-$16.14M-$17.50M-$18.36M-$15.49M-$17.81M
Shares outstanding5.90M5.90M2.73M2.67M66.40M50.98M1.69M—
Cash flow statement
Operating cash flow-$1.05M-$2.08M-$620,000-$2.28M-$1.05M-$1.50M-$8.25M-$997,000
Investing cash flow———————-$20,000
Financing cash flow-$123,000$7.41M$359,000$569,000$1.67M-$84,000$40.27M$936,000
Depreciation & amortization$2,000$3,000$3,000$4,000$3,000$8,000$7,000$8,000
Stock-based compensation$208,000$302,000$331,000$286,000$360,000$512,000$396,000$415,000
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.